Drugs / CD138-CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03473496 | Mar 2018 → Jan 2020 | plasma cell myeloma | Zhujiang Hospital | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD138-CART | “one kind of BCMA-CART,CD138-CART,CD56-CART or CD38-CART,subjects will receive 10\^6-10\^7/Kg transduced CAR T cells at one time.” NCT03473496 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor T(CAR-T) Cells Therapy” NCT03473496 ↗ |